יחס חוב לטווח קצר להון עצמי: Vistagen (VTGN)

This daily price chart for Vistagen Therapeutics (VTGN) is based on the company's ownership of exclusive patents in the field of neurosteroids, while the short-term debt-to-equity ratio stands at 0.03. Growth is expected to be driven by upcoming final trials of an innovative treatment for social anxiety disorder. Business development relies on partnerships with specialized scientific centers to refine emergency relief medications.

This ratio determines the share of short-term borrowings within the equity structure, measuring the ability of the company's assets to cover urgent credit obligations without risking insolvency. By analyzing the ratio of short-term liabilities to equity, investors assess the financial stability of Vistagen Therapeutics (VTGN), which is critical for management when financing the development of innovative nasal sprays for anxiety disorders.